Abstract
Introduction: Adiponectin (ADPN) is secreted by adipocytes and has anti-atherogenic, anti-inflammatory and insulin-sensitizing properties. Recent data suggested high plasma ADPN levels are associated with poorer outcomes. We hypothesize that body mass index (BMI) may impact the prognostic value of ADPN in patients with chronic systolic heart failure. Methods: We evaluated 139 patients enrolled in the ADEPT study with chronic systolic heart failure (LVEF≤35%, NYHA functional class II-IV). Plasma ADPN levels were determined by sandwich enzyme-linked immunosorbent assay (Quantikine ELISA, R&D Systems, Minneapolis MN).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
